Skip to main content
Top
Published in: BMC Ophthalmology 1/2018

Open Access 01-12-2018 | Research article

Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients

Corneal endothelium after dexamethasone implant injection

Authors: Hatice Ayhan Güler, Nurgül Örnek, Kemal Örnek, Nesrin Büyüktortop Gökçınar, Tevfik Oğurel, Mehmet Erhan Yumuşak, Zafer Onaran

Published in: BMC Ophthalmology | Issue 1/2018

Login to get access

Abstract

Background

To assess corneal endothelial cell changes after intravitreal dexamethasone (DEX) implant (Ozurdex®) injection in patients with macular edema secondary to retinal vein occlusion (RVO).

Methods

Twenty-two eyes of 22 patients were assessed prospectively after intravitreal 0.7 mg DEX implant injection. Twenty-two eyes of 22 healthy volunteers served as control group. Corneal endothelial cell parameters including endothelial cell density (ECD), coefficient of variation of cell size (CV), percentage of hexagonality (Hex) and central corneal thickness (CCT) were analyzed before and 1 and 3 months after injection by specular microscopy. The results of the study were compared statistically.

Results

There were 17 (77.3%) patients with branch RVO and 5 (22.7%) patients with central RVO. Mean intraocular pressure (IOP) was 14.73 mmHg before injection, 17.05 mmHg at 1 month and 17.15 mmHg at 3 months after injection. Mean IOP at 1 and 3 months were significantly higher than pre-injection value (p = 0.002 and p = 0.003, respectively). There was a statistically significant reduction in mean ECD at 3 months after injection compared to pre-injection and 1 month (p = 0.013, p = 0.009, respectively) in the injected eyes. Mean ECD showed no significant difference in the uninjected fellow eyes during the follow up (p>0.05). Mean CV and Hex did not reveal a statistically significant difference in injected and uninjected fellow eyes (p > 0.05). No significant change was observed in mean CCT values during the follow up (p = 0.8).

Conclusion

Intravitreal dexamethasone implant may cause a transient reduction in corneal endothelial cell density in short term without changing cell morphology.
Literature
1.
go back to reference Kapoor KG, Wagner MG, Wagner AL. The sustained-release dexamethasone implant: expanding indications in vitreoretinal disease. Semin Ophthalmol. 2015;30(5–6):475–81.CrossRefPubMed Kapoor KG, Wagner MG, Wagner AL. The sustained-release dexamethasone implant: expanding indications in vitreoretinal disease. Semin Ophthalmol. 2015;30(5–6):475–81.CrossRefPubMed
2.
go back to reference London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351–66.CrossRefPubMed London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351–66.CrossRefPubMed
3.
go back to reference Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release. 2007;117(1):68–79.CrossRefPubMed Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release. 2007;117(1):68–79.CrossRefPubMed
4.
go back to reference Mutsaers HA, Tofighi R. Dexamethasone enhances oxidative stress-induced cell death in murine neural stem cells. Neurotox Res. 2012;22(2):127–3724.CrossRefPubMed Mutsaers HA, Tofighi R. Dexamethasone enhances oxidative stress-induced cell death in murine neural stem cells. Neurotox Res. 2012;22(2):127–3724.CrossRefPubMed
5.
go back to reference Ruiz LM, Bedoya G, Salazar J, de García OD, Patiño PJ. Dexamethasone inhibits apoptosis of human neutrophils induced by reactive oxygen species. Inflammation. 2002;26(5):215–22.CrossRefPubMed Ruiz LM, Bedoya G, Salazar J, de García OD, Patiño PJ. Dexamethasone inhibits apoptosis of human neutrophils induced by reactive oxygen species. Inflammation. 2002;26(5):215–22.CrossRefPubMed
6.
go back to reference Chen WL, Lin CT, Yao CC, Huang YH, Chou YB, Yin HS, Hu FR. In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and Na+-K+-ATPase activity of bovine corneal endothelial cells. Ocul Immunol Inflamm. 2006;14(4):215–23.CrossRefPubMed Chen WL, Lin CT, Yao CC, Huang YH, Chou YB, Yin HS, Hu FR. In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and Na+-K+-ATPase activity of bovine corneal endothelial cells. Ocul Immunol Inflamm. 2006;14(4):215–23.CrossRefPubMed
7.
go back to reference Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C, Andrew R. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci. 2000;41(7):1629–38.PubMed Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C, Andrew R. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci. 2000;41(7):1629–38.PubMed
8.
go back to reference Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259–66.CrossRefPubMed Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259–66.CrossRefPubMed
9.
go back to reference Ilhan N, Coskun M, Ilhan O, Ayhan Tuzcu E, Daglıoglu MC, Elbeyli A, Keskin U, Oksuz H. Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion. Cutan Ocul Toxicol. 2015;34(4):294–7.CrossRefPubMed Ilhan N, Coskun M, Ilhan O, Ayhan Tuzcu E, Daglıoglu MC, Elbeyli A, Keskin U, Oksuz H. Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion. Cutan Ocul Toxicol. 2015;34(4):294–7.CrossRefPubMed
10.
go back to reference Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and managment. J Thromb Haemost. 2010;8(9):1886–94.CrossRefPubMed Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and managment. J Thromb Haemost. 2010;8(9):1886–94.CrossRefPubMed
11.
go back to reference Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012;23(3):175–81.CrossRefPubMed Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012;23(3):175–81.CrossRefPubMed
12.
go back to reference Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexametasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthamology. 2010;117(6):1134–46.CrossRef Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexametasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthamology. 2010;117(6):1134–46.CrossRef
13.
go back to reference Campochiaro PA. Anti-vascular endothelial growht factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227(Suppl1):30–5.CrossRefPubMed Campochiaro PA. Anti-vascular endothelial growht factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227(Suppl1):30–5.CrossRefPubMed
14.
go back to reference Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, for the OZURDEX GENEVA Study Group. Dexametasone intravitreal implant in patients with maculer edema related to branch or central retinal vein occlusion twelve month study results. Ophtalmology. 2011;118(12):2453–60.CrossRef Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, for the OZURDEX GENEVA Study Group. Dexametasone intravitreal implant in patients with maculer edema related to branch or central retinal vein occlusion twelve month study results. Ophtalmology. 2011;118(12):2453–60.CrossRef
15.
go back to reference Chang Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Pharmocokinetics and pharmocodynamics of a sustained release dexametasone intravitreal implant. Invest Opthalmol Vis Sci. 2011;52(7):80–6.CrossRef Chang Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Pharmocokinetics and pharmocodynamics of a sustained release dexametasone intravitreal implant. Invest Opthalmol Vis Sci. 2011;52(7):80–6.CrossRef
16.
go back to reference Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side effects of the dexamethasone implant. Ocul Immunol Inflamm. 2016;5:1–7. Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side effects of the dexamethasone implant. Ocul Immunol Inflamm. 2016;5:1–7.
17.
go back to reference Park YW, Jeong MB, Lee ER, Lee Y, Ahn JS, Kim SH, Seo K. Acute changes in central corneal thickness according to experimental adjustment of intraocular pressure in normal canine eyes. J Vet Med Sci. 2013;75(11):1479–83.CrossRefPubMedPubMedCentral Park YW, Jeong MB, Lee ER, Lee Y, Ahn JS, Kim SH, Seo K. Acute changes in central corneal thickness according to experimental adjustment of intraocular pressure in normal canine eyes. J Vet Med Sci. 2013;75(11):1479–83.CrossRefPubMedPubMedCentral
18.
go back to reference Ytteborg J, Dohlman C. 1965. Corneal edema and intraocular pressure. II. Clinical results. Arch Ophthalmol. 1965;74(4):477–84.CrossRefPubMed Ytteborg J, Dohlman C. 1965. Corneal edema and intraocular pressure. II. Clinical results. Arch Ophthalmol. 1965;74(4):477–84.CrossRefPubMed
19.
go back to reference Franco S, Lira M. Biomechanical properties of the cornea measured by the ocular response analyzer and their association with intraocular pressure and the central corneal curvature. Clin Exp Optom. 2009;92(6):469–75.CrossRefPubMed Franco S, Lira M. Biomechanical properties of the cornea measured by the ocular response analyzer and their association with intraocular pressure and the central corneal curvature. Clin Exp Optom. 2009;92(6):469–75.CrossRefPubMed
20.
go back to reference Zavala J, López Jaime GR, Rodríguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: developmental strategies for regeneration. Eye (Lond). 2013;27(5):579–88.CrossRef Zavala J, López Jaime GR, Rodríguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: developmental strategies for regeneration. Eye (Lond). 2013;27(5):579–88.CrossRef
21.
go back to reference Guzel H, Bakbak B, Koylu MT, Gonul S, Ozturk B, Gedik S. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endotelium in the treatment of diabetic macular edema. Cutan Ocul Toxicol. 2017;36(1):5–8.CrossRefPubMed Guzel H, Bakbak B, Koylu MT, Gonul S, Ozturk B, Gedik S. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endotelium in the treatment of diabetic macular edema. Cutan Ocul Toxicol. 2017;36(1):5–8.CrossRefPubMed
22.
go back to reference Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, Gómez-Sangil Y, Germain F, Montes-Mollón MA, Teus MA. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea. 2010;29(8):849–52.CrossRefPubMed Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, Gómez-Sangil Y, Germain F, Montes-Mollón MA, Teus MA. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea. 2010;29(8):849–52.CrossRefPubMed
23.
go back to reference Michalska- Małecka K, Gaborek A, Nowak M, Halat T, Pawłowska M, Śpiewak D. Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion. Clin Interv Aging. 2016;23(11):699–705.CrossRef Michalska- Małecka K, Gaborek A, Nowak M, Halat T, Pawłowska M, Śpiewak D. Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion. Clin Interv Aging. 2016;23(11):699–705.CrossRef
24.
go back to reference Solomon A, Solberg Y, Belkin M, Landshman N. Effect of corticosteroids on healing of the corneal endothelium in cats. Graefes Arch Clin Exp Ophthalmol. 1997;235(5):325–9.CrossRefPubMed Solomon A, Solberg Y, Belkin M, Landshman N. Effect of corticosteroids on healing of the corneal endothelium in cats. Graefes Arch Clin Exp Ophthalmol. 1997;235(5):325–9.CrossRefPubMed
25.
go back to reference Kang H, Lee MW, Byeon SH, Koh HJ, Lee SC, Kim M. The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1819–25. Kang H, Lee MW, Byeon SH, Koh HJ, Lee SC, Kim M. The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®). Graefes Arch Clin Exp Ophthalmol. 2017;255(9):1819–25.
26.
go back to reference Rahimy E N, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017;28(3):246–51.CrossRefPubMed Rahimy E N, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017;28(3):246–51.CrossRefPubMed
Metadata
Title
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients
Corneal endothelium after dexamethasone implant injection
Authors
Hatice Ayhan Güler
Nurgül Örnek
Kemal Örnek
Nesrin Büyüktortop Gökçınar
Tevfik Oğurel
Mehmet Erhan Yumuşak
Zafer Onaran
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2018
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-018-0905-0

Other articles of this Issue 1/2018

BMC Ophthalmology 1/2018 Go to the issue